By: IPP Bureau
Last updated : October 13, 2025 4:53 pm
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Roche announced that it will present new data from more than 30 abstracts across over 10 different cancer types at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place from 17–21 October in Berlin, Germany.
These data highlight Roche’s continued commitment to advancing scientific innovation and delivering transformative treatments for some of the most challenging cancers, including breast, lung, gastrointestinal, and genitourinary cancers. Among the key highlights, Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant.
This is the first positive head-to-head phase III trial to investigate a selective oestrogen receptor (ER) degrader-containing regimen against a standard-of-care combination in the post-cyclin-dependent kinase inhibitor setting for people with ER-positive, HER2-negative, locally advanced, or metastatic breast cancer.
The study achieved both co-primary endpoints, demonstrating statistically significant and clinically meaningful improvements in progression-free survival in both the intention-to-treat and ESR1-mutated populations. These findings will be presented as a late-breaking oral abstract.
Roche will also present results from the IMvigor011 trial, the first global phase III study exploring a circulating tumour DNA (ctDNA)-guided approach to post-surgery treatment in muscle-invasive bladder cancer (MIBC).
Topline results show that patients with detectable ctDNA who received Tecentriq (atezolizumab) experienced statistically significant and clinically meaningful improvements in both disease-free survival (DFS) and overall survival (OS). These data will be featured as part of the Presidential Symposium.
Further, final overall survival data from the pivotal ALEX study of Alecensa (alectinib) will be presented. Alecensa is an established first-line treatment and standard of care for people with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These results will be shared as a late-breaking oral abstract and published simultaneously in the Annals of Oncology.
In addition, updated findings from the phase III ALINA study will reinforce the role of adjuvant Alecensa as the standard of care for patients with resected ALK-positive NSCLC. After a median follow-up of approximately four years, the disease-free survival data for Alecensa compared with chemotherapy will be presented.